Arcellx is a clinical-stage biotech company developing immunotherapies for cancer and other incurable diseases. Its lead product candidate, CART-ddBCMA, is in phase 1 clinical trial for relapsed or refractory multiple myeloma. The company is also developing immunotherapeutic combinations for acute myeloid leukemia, myelodysplastic syndrome, and solid tumors. Arcellx was formerly known as Encarta Therapeutics and is headquartered in Maryland.